“The third quarter marked an important inflection point for Kalaris,” said Andrew Oxtoby, Chief Executive Officer of Kalaris Therapeutics (KLRS). “Most importantly, we began enrolling our Phase 1b/2 multiple ascending dose trial of TH103 in neovascular age-related Macular Degeneration. This Phase 1b/2 trial is designed to build on our ongoing Phase 1a single ascending dose trial; we look forward to reporting initial clinical data from our Phase 1a trial by the end of this year, including safety, preliminary efficacy, and pharmacokinetics.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLRS:
- Kalaris Therapeutics Appoints New CFO Matthew Gall
- Kalaris Therapeutics appoints Gall as Chief Financial Officer
- Kalaris Therapeutics initiated with an Outperform at Citizens JMP
- Optimistic Buy Rating for Kalaris Therapeutics: Advancements in TH103 for nAMD
- Kalaris Therapeutics now enrolling Phase 1b/2 MAD study of TH103